SULF-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SULF-10 (SULF-10).
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
| Metabolism | Primarily renal excretion as unchanged drug; hepatic metabolism is minimal. |
| Excretion | Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15% |
| Half-life | Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment |
| Protein binding | Protein binding: 20-50% (primarily to albumin) |
| Volume of Distribution | Volume of distribution: 0.2-0.4 L/kg (low, indicating limited tissue distribution) |
| Bioavailability | Topical ophthalmic: minimal systemic absorption (<5%); oral: not applicable for this formulation |
| Onset of Action | Topical ophthalmic: within 30 minutes; oral: 2-4 hours (not a typical route for SULF-10) |
| Duration of Action | Topical ophthalmic: 4-6 hours; systemic absorption can prolong effects if applied to large areas |
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific renal dose adjustment recommended for topical ophthalmic use; systemic absorption is minimal. |
| Liver impairment | No specific hepatic dose adjustment recommended for topical ophthalmic use; systemic absorption is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients not established; use same dosing as adults when prescribed, but consider age-appropriate supervision. |
| Geriatric use | No specific geriatric dose adjustment recommended for topical ophthalmic use; use with caution if concurrent renal or hepatic impairment, but systemic absorption is minimal. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SULF-10 (SULF-10).
| Breastfeeding | Minimal systemic absorption suggests negligible excretion into breast milk. M/P ratio is not established due to low bioavailability. Topical use is considered compatible with breastfeeding; avoid application to breast area to prevent infant ingestion. Discontinue use if infant develops rash or diarrhea. |
| Teratogenic Risk | SULF-10 (Sulfacetamide 10%) is a topical sulfonamide antibiotic. Systemic absorption is minimal (<4%), and teratogenic risk is considered low. In first trimester, theoretical risk of neural tube defects due to folate antagonism exists if significant systemic absorption occurs; however, topical use generally poses negligible fetal exposure. No specific human data indicate increased malformations. In second and third trimesters, risk of kernicterus in neonates due to bilirubin displacement is theoretical but unlikely with topical use. Overall, classified as FDA Pregnancy Category C. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to sulfonamides or any component; infants less than 2 months of age (except for congenital toxoplasmosis).
| Precautions | Hypersensitivity reactions including Stevens-Johnson syndrome; photosensitization; overgrowth of nonsusceptible organisms including fungi; prolonged use may result in corneal toxicity. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use. If used on large areas or compromised skin, monitor for signs of sulfonamide toxicity (rash, urticaria, Stevens-Johnson syndrome, agranulocytosis). In pregnancy, monitor fetal growth and development with routine ultrasound if prolonged use. |
| Fertility Effects | No known adverse effects on fertility based on available data. Systemic absorption minimal, unlikely to impact reproductive function. |